article thumbnail

Medicare Part D: Navigating Plans and Potential Gaps in 2025

Pharmaceutical Commerce

With a 26% decline in prescription drug plans from 2024 to 2025, navigating potential gaps and accessing care remains vital for low income patients.

article thumbnail

Cigna's Express Scripts to cross out AbbVie's Humira from some formularies in 2025, opting to go with biosims instead

Fierce Pharma

When CVS Caremark removed AbbVie’s Humira from its national commercial formularies back in April, biosimilar prescriptions picked up at a whirlwind pace. Following CVS Caremark's lead, Cigna's pharmacy benefit manager unit will nix Humira from formularies in favor of Humira biosimilars from Boehringer Ingelheim, Teva and Sandoz.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA accepts Eisai's subcutaneous Leqembi filing, sets January 25 decision date

Fierce Pharma

The FDA assigned the subcutaneous Leqembi application a Prescription Drug User Fee Act decision date of January 25, 2025. About a month after Eisai initiated a rolling FDA application for its subcutaneous form of Leqembi, the U.S. agency has accepted the filing. |

FDA 182
article thumbnail

New Reimbursement Opportunities for Digital Mental Health Treatment in 2025: CMS’ Final Rule

Nixon Gwilt Law

CMS issued its 2025 Medicare Physician Fee Schedule (the “2025 MPFS” or “Final Rule”) on November 1, 2024. The Final 2025 MPFS contains some modifications and clarifications to several elements of the original proposal released in July 2024 (the “Proposed Rule”), which we discussed in this earlier post.

FDA 52
article thumbnail

New Reimbursement Opportunities for Digital Mental Health Treatment in 2025: CMS’ Final Rule

Nixon Gwilt Law

CMS issued its 2025 Medicare Physician Fee Schedule (the “2025 MPFS” or “Final Rule”) on November 1, 2024. The Final 2025 MPFS contains some modifications and clarifications to several elements of the original proposal released in July 2024 (the “Proposed Rule”), which we discussed in this earlier post.

FDA 52
article thumbnail

Medicare Advantage Star Ratings Drop Again

MedCity News

For 2025, the average star rating for Medicare Advantage Prescription Drug contracts was 3.92, compared to 4.07 for 2024, 4.14 for 2023 and 4.37 The post Medicare Advantage Star Ratings Drop Again appeared first on MedCity News.

article thumbnail

Cosette acquires worldwide rights to Endoceutics’ Intraros prescription drug

Pharma Leaders

Cosette Pharmaceuticals has acquired the worldwide rights to prescription drug, Intraros, from Endorecherche’s subsidiary Endoceutics. It is expected to be launched in Asian market in 2025. Intrarosa is said to be the only prescription drug that provides estrogen as well as androgen to treat moderate-to-severe dyspareunia.